These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Tegaserod in treatment of women with irritable bowel syndrome].
    Author: Munck LK, Ainsworth MA.
    Journal: Ugeskr Laeger; 2007 Jun 04; 169(23):2190-2. PubMed ID: 17592683.
    Abstract:
    Irritable bowel syndrome (IBS) is a chronic, relapsing disease characterised by abdominal pain and altered bowel movements. This review assesses the clinical trials of the partial serotonin receptor agonist tegaserod in women with constipation type IBS. Significantly more women treated with tegaserod obtained sufficient relief from symptoms during at least 2 out of 4 weeks, but the absolute therapeutic gain of approximately 10 percent was not deemed clinically relevant. Two marketing authorisation applications in the European Union have been rejected due to the minor therapeutic gain. Tegaserod was removed from the market in the USA in March 2007 due to an increased risk of severe cardiovascular adverse events.
    [Abstract] [Full Text] [Related] [New Search]